←
Arpita Desai439 posts
Arpita Desai avatar

Arpita Desai

@ADESAIONCMD

Medical Director of GU Medical Oncology, Associate Professor @UCSF with focus on #KidneyCancer. Alum of @UChicago. RTs not endorsements

◷ Joined September 2022
Arpita Desai avatar
Arpita Desai@ADESAIONCMD·Jun 2

What an absolute honor to chair the papillary RCC Education Session at #ASCO26! 🙌🔬 Papillary renal cell carcinoma is a disease that demands our attention, and this session covered the full spectrum 🧬 — biology ➡️ frontline ➡️ refractory disease. I was thrilled to review subsequent lines + novel therapeutic approaches for refractory papillary RCC 💉💙, including the emerging strategies and clinical trial opportunities that give me so much hope for our patients. 🌟 Huge thanks to my incredible co-faculty Dr. Ramaprasad Srinivasan 🧠 & @charlesbnguyen for such an engaging discussion — collaboration like this is what moves the field forward! 🚀 #KidneyCancer #RCC #GUOncology @ASCO @urotoday @JCO_ASCO @ASCOPost @charlesbnguyen @OncoAlert @UCSF

Post attachment
ANCO avatar
⟳ Arpita Desai retweeted
ANCO@ANCO_News·Sep 19

We’re kicking off the 1st Northern California Genitourinary Cancer Research Forum! Looking forward to a day of case-based discussions, clinical trial insights, and collaboration across the Northern California GU oncology community. #ANCO #GUForum26

Post attachment
Arpita Desai avatar
Arpita Desai@ADESAIONCMD·Sep 19

🎤 An inspiring keynote at the 1st Northern California Genitourinary Cancer Research Forum from @montypal on The Art of Clinical Trial Accrual for Genitourinary Malignancies. Clinical trials are how we turn scientific discovery into better care. But a trial can only change lives if we find ways to bring it to the patients who need it. Grateful for the reminder that accrual is not just a metric. It is access, opportunity, and hope. 🧬 @ANCO_News @UCSFCancer

Post attachmentPost attachmentPost attachmentPost attachment
Sumanta K. Pal, MD, FASCO avatar
⟳ Arpita Desai retweeted
Sumanta K. Pal, MD, FASCO@montypal·Sep 19

A simply brilliant meeting - #NorCalGU26 - hosted by #DrMamtaParikh & @ADESAIONCMD. Kicking off the day with a brilliant #prostatecancer session with @mdallera & @DivyaParikhMD including experts from @KPSCalResearch, @UCSFCancer, @UCD_Cancer & @StanfordCancer. Honored to deliver our perspective from the @SoCalGUResearch lens, with previous meetings (#SoCalGU24, #SoCalGU25 & #SoCalGU26) now in the books! @sandysrimd @CMitsiadesLab

Post attachmentPost attachmentPost attachmentPost attachment
Toni Choueiri, MD avatar
⟳ Arpita Desai retweeted
Toni Choueiri, MD@DrChoueiri·Jul 27

1)🚨 Results from #RADICAL (#A031801) are now published in @JCO_ASCO, led by @DrRanaMcKay and @ALLIANCE_org A THREAD! Bone metastases occur in ~30% of patients with metastatic #RCC and are associated with increased skeletal morbidity and worse survival. RADICAL trial evaluated whether adding radium-223, an α-emitting bone-seeking radiopharmaceutical, to VEGF TKI Cabozantinib could improve outcomes in patients with metastatic RCC + bone metastases Link: ascopubs.org/doi/10.1200/JCO… @OncoAlert @OncBrothers @AUC3_Official @Uromigos @ASCO

Post attachment
Toni Choueiri, MD avatar
⟳ Arpita Desai retweeted
Toni Choueiri, MD@DrChoueiri·Jul 27

8) This study is the culmination of a 10+year work with @DrRanaMcKay, now @UCSDCancer It all started with a conversation back in 2013, when Rana was a junior attending, pregnant with her 2nd child, and passionately discussing one of the biggest unmet needs in kidney cancer; patients with bone metastases, who consistently had poor outcomes despite available systemic therapies. That conversation sparked a decade of work dedicated to understanding the biology of bone metastases.

KidneyCAN avatar
⟳ Arpita Desai retweeted
KidneyCAN@kidneycan·Jul 24

The future of immunotherapy continues to evolve! Our fifth session explored emerging approaches that could shape the next generation of kidney cancer treatment, from the microbiome and novel antibody therapies to tumor antigens and AI-driven protein design. The pace of innovation in immunotherapy continues to inspire new possibilities for patients and researchers alike. @HHammersMD @UTSWMedCenter @BraunMDPhD @YaleCancer @DanaFarber #KCRS26 #AcceleratingCures

Tom Powles avatar
⟳ Arpita Desai retweeted
Tom Powles@tompowles1·Jul 23

Quality of life data from LITESPARK-22 #KCRS26 (pembro+belzutifan in adjuvant RCC). Three different tools (FKSI/EORTCQLQ30/GP5) show a temporary dip in global and physical/role function QOL while on therapy, which didn’t hit predefined clinically meaningful levels. This is consistent with the reversible belzutifan toxicity signal (fatigue/anaemia). There is a need to look at quality of life analysis in different ways @BethN01 @DrChoueiri @montypal @Annals_Oncology @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment